Autoimmune neurological disorders encompass disorders of nervous system caused by dysfunction of the immune system. Through this…
In the autoimmune kidney disease Membranous Nephropathy (MN), the immune system launches an attack against the glomerulus of the kidney, which normally aids in filtering fluids and wastes. In 2009, autoantibodies against phospholipase A2 receptor (PLA2R) were discovered to be responsible for MN and have been shown to have a high diagnostic value.
Rheumatoid Arthritis (RA) is caused when the immune system sends antibodies to attack your joints, leading to joint destruction and disability. While there is no current cure for RA, treatment is possible. Treatment of RA is best done within 3 to 6 months after symptoms start, since permanent joint damage can occur within the first 2 years. This blog will discuss the common antibodies which are tested for in RA diagnosis, and highlight additional uses of antibody testing in RA.
Autoimmune liver diseases (ALD) occur when the immune system turns against liver cells, leading to inflammation. Types of ALD include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). The detection of specific disease-associated antibodies allows for a differential diagnosis of the culprit ALD, and helps to ensure proper patient treatment. Here we discuss the specific autoantibodies associated with either AIH, PBC, or PSC, as well as the techniques available for their detection.
KOL Spotlight Interviews is a segment where we interview experts in various fields on their expertise and insights that continue to help shape the diagnostics and pharmaceutical industries. This month, we have the pleasure of welcoming Dr. Animesh Sinha, a renowned dermatologist from University at Buffalo. Below, we will learn more about diagnostic methods for autoimmune bullous dermatoses conditions.
Meet Lisa Ann, a patient who was diagnosed with a rare autoimmune skin blistering disease after many misdiagnoses. She shares her story from the first symptoms and frustrations, testing and multiple doctor visits, and how she lives and manages this condition today. Check out this Patient Journey to hear from Lisa Ann and learn what diagnostic tests are available for these rare skin diseases.
There is a need for continuous monitoring of therapeutic levels of TNF-α inhibitors to promote individualized treatment while affirming that patients receive the most accurate and cost-effective regimen available. With the MabTrack ELISA, clinicians can make effective adjustments based on semi-quantitative results and can facilitate simplified decision-making with their patients for improved long-term response.